Attached files
| file | filename |
|---|---|
| EX-99.1 - Actavis, Inc. | v171894_ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
To Section 13 or 15(d) Of the Securities and Exchange Act Of 1934
January
21, 2010
Date of
Report (Date of earliest event reported)
WATSON
PHARMACEUTICALS, INC.
(Exact
name of registrant as specified in its charter)
|
Nevada
|
001-13305
|
95-3872914
|
|
(State
or other Jurisdiction
of
Incorporation)
|
(Commission
File Number)
|
(IRS
Employer
Identification
Number)
|
|
311
Bonnie Circle
Corona,
California
(Address
of principal executive
offices)
|
92880
(Zip
Code)
|
(951)
493-5300
(Registrant’s
telephone number, including area code)
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Item
2.02 Results of
Operations and Financial Condition.
On
January 21, 2010, Watson Pharmaceuticals, Inc. (the “Company”) issued a press
release providing an overview of its global operations and outlook for
2010. A copy of the Company’s press release is attached to this
report as Exhibit 99.1 and incorporated herein by reference.
In its
press release, the Company included non-GAAP financial measures, as defined in
Regulation G promulgated by the U. S. Securities and Exchange
Commission. The Company believes that its inclusion of non-GAAP
financial measures provides useful supplementary information to and facilitates
analysis by investors in evaluating the Company’s performance and
trends. The Company uses both GAAP financial measures and the
disclosed non-GAAP financial measures internally to evaluate and manage the
Company’s operations and to better understand its business. These
non-GAAP financial measures are in addition to, not a substitute for, or
superior to, measures of financial performance prepared in accordance with
GAAP.
The
information in this report (including the exhibit) is furnished pursuant to Item
2.02 and shall not be deemed to be “filed” for purposes of Section 18 of the
Securities Exchange Act of 1934 (the “Exchange Act”), nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933 or the
Exchange Act, except as shall be expressly set forth by specific reference in
such filing.
Item
9.01 Financial
Statements and Exhibits.
d. Exhibits:
|
|
99.1
|
Watson Provides Overview of
Global Operations; Delivers Outlook for Continued
Growth
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Dated:
January 21, 2010
|
WATSON
PHARMACEUTICALS, INC.
|
|
|
By:
|
/s/ R. Todd Joyce
|
|
|
R.
Todd Joyce
|
||
|
Senior
Vice President – Chief
Financial Officer
|
||
|
Principal
Accounting Officer and Principal Financial
Officer
|
3
EXHIBIT
INDEX
|
Exhibit
No.
|
Description
|
|
|
99.1
|
Watson
Provides Overview of Global Operations; Delivers Outlook for Continued
Growth
|